Direct Meds Tirzepatide Review: Cost, Oral Option & Honest Verdict (2026)

Direct Meds charges $399 a month for compounded tirzepatide injections, sold as 30-, 60- or 90-day supplies with no membership fee stacked on top. It is one of the few programs offering an oral/sublingual tirzepatide route as well as the standard injection, though it publishes no separate price for that form.

What Direct Meds is

Direct Meds is a compounded-only telehealth pharmacy, launched in 2024, that offers both oral/sublingual and injectable tirzepatide, plus compounded semaglutide. Fees are described as all-inclusive with no separate membership. Two honest caveats up front: the figures below are stated by the company rather than confirmed on a live public price page during our review, and the brand operates across multiple domains — so we present its numbers with that caveat rather than as independently verified.

The compounded-vs-brand question

Two very different products share the name tirzepatide:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

Everything Direct Meds dispenses is compounded. That distinction matters more in 2026: the FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. The oral/sublingual route in particular lacks the injectable's robust absorption and efficacy evidence.

What Direct Meds costs in 2026

Per the company, compounded tirzepatide runs roughly $224/month sublingual or ~$399/month injectable, with compounded semaglutide around $179–$297/month (an intro promo around $147). Fees are described as all-inclusive with no separate membership, which is a plus for predictability. The important caveat is that these are company-stated figures we could not confirm on a live public price page, so treat them as a starting point to verify directly rather than a firm quote.

For context, LillyDirect sells brand Zepbound self-pay vials at roughly $299–$449/month depending on dose (prices in effect since December 1, 2025; 28-day supply). For the full cash-price picture, see our Zepbound cost and savings guide.

How the care model holds up

Direct Meds' strengths are a rare oral/sublingual tirzepatide option in addition to injectable, all-inclusive pricing with no separate membership fee, and both molecules available. The trade-offs are significant: the tirzepatide is compounded and not FDA-approved; the pricing is company-stated and could not be independently verified on a live page; it is a newer operator (2024) with an ambiguous footprint across multiple domains; and the states served are not disclosed. Those verification gaps are the main reason to proceed carefully and confirm everything in writing. Tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

FDA warning letter, September 2025

FDA issued directmeds.com, Inc. dba DirectMeds a warning letter in September 2025, posted under the subject line Unlawful Sale of Unapproved and Misbranded Drugs³. We independently confirmed it against FDA's own published warning-letter record rather than repeating a second-hand report, and the reference at the foot of this page links straight to FDA's copy.

We are not going to paraphrase FDA's findings back to you — the letter is public and reading the agency's own words beats reading ours. What matters for how you use this page is that the letter exists and that we are telling you about it while still linking to Direct Meds on commission. Read it alongside the verification gaps below rather than instead of them; the affiliate relationship has not changed, and the notice travels with Direct Meds on every ranking, index and card where we link to the company, not just here.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Direct Meds is worth a look mainly if you specifically want a rare oral/sublingual tirzepatide option on an all-inclusive fee — and you are comfortable with a compounded, non-FDA-approved product and with the verification gaps. Those gaps are the real reservation: company-stated pricing we could not confirm on a live page, a newer operator with an ambiguous multi-domain footprint, and undisclosed states served. Verify everything in writing before paying. If you prefer a provider with transparent, verifiable pricing and included support, weigh CoreAge Rx; if you specifically want brand tirzepatide, price it against LillyDirect. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.